Allurion’s Swallowable Gastric Balloon Linked With 14% Average Weight Loss

A study conducted in 3,716 patients from 26 centers in nine countries treated with Allurion’s swallowable gastric balloon and lifestyle program revealed a 14% average total body weight loss (TBWL) after four months. The study is the largest of its kind ever conducted and reports a weight loss that is now recognized as sufficient to put patients into remission of Type 2 diabetes, according to the company.

“With an average weight loss of 14% in just four months across nearly 4,000 patients, the Allurion Program has once again been shown to deliver life-changing results across a broad population,” Allurion Co-Founder/CEO Dr. Shantanu Gaur. “With weight loss of 10%-15% now recognized as a driver for diabetes remission, it is clear that the Allurion Program now has a much wider role to play in metabolic health.”
 
The Allurion Program—which consists of a gastric balloon that requires no surgery, no endoscopy,ⁱ and no anaesthesia alongside a fully supported lifestyle program—was also found to significantly improve metabolic parameters, with a consistent safety profile in a diverse, global population.
 
The study also concluded the Allurion Program’s unique Virtual Care Suite—a remote patient monitoring system and telehealth platform that enables ongoing support in nutrition, behaviour change, activity and healthy sleep patterns—also contributes to improved outcomes.
 
This study provides further evidence to support the broader metabolic benefits of the Allurion Program. A previous study in 226 patients with Type 2 diabetes and prediabetes demonstrated that on average, the Allurion Program brought both diseases into remission.ⁱⁱ
 
Presented ahead of World Diabetes Day, this study follows a new consensus report published last month by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) which recommended the need for a greater emphasis on weight loss as part of a holistic approach to diabetes management.
 
The consensus report confirmed that a weight loss of 5% to15% should be a primary target of management for many people living with Type 2 Diabetesⁱⁱⁱ and a higher magnitude of weight loss confers better outcomes. Weight loss of 5% to 10% confers metabolic improvement and a weight loss of 10% to15% or more can have a disease-modifying effect and lead to remission of diabetes.^iv
 
“Obesity and Type 2 Diabetes are pandemics of unprecedented magnitude, and they often afflict patients simultaneously. Often, current treatments for obesity and diabetes are not enough or are refused by patients because of their invasive nature. This study further strengthens the growing evidence that the Allurion Program offers a compelling treatment for both conditions,” said Dr. Roberta Ienca of Clinica Nuova Villa Claudia in Rome, Italy.
 
Allurion Chief Commercial Officer Benoit Chardon said the data underscores the wider market opportunity for The Allurion Program. “The Allurion Program provides patients with an effective tool to reduce hemoglobin A1c (HbA1c) and put both pre-diabetes and Type 2 Diabetes into remission. These results underscore the benefits of the Allurion Program beyond weight loss and highlight how quickly the Allurion Program can have a significant health impact on patients,” he stated.
 
Allurion is dedicated to ending obesity. The Allurion Program is a 360-degree weight loss experience featuring the Allurion Gastric Balloon, the world’s first and only swallowable, procedureless* gastric balloon for weight loss, the Allurion Virtual Care Suite including the Allurion Mobile App for consumers, Allurion Insights for clinicians featuring the Iris AI Platform, and the Allurion Connected Scale and Health Tracker devices. The Allurion VCS is now available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional.
 
Allurion is a trademark of Allurion Technologies Inc. 

References 
ⁱ In rare cases, the Allurion Balloon may require endoscopic or surgical intervention for removal
ⁱⁱ Ienca R, Rosa M, Pagan Pomar AA, Hansoulle J, and Caballero A. Emerging Role of the New Swallowable Gastric Balloon in Type 2 Diabetes and Prediabetes Treatment. Poster 114. Presented at TOS Obesity Week 2021.
ⁱⁱⁱ Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet 2022;399:394–405
^iv Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet 2022;399:394–405